WO2015174585A1 - 보체인자 b 단백질에 특이적으로 결합하는 항체 및 카보하이드레이트 안티젠 19-9 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 - Google Patents
보체인자 b 단백질에 특이적으로 결합하는 항체 및 카보하이드레이트 안티젠 19-9 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 Download PDFInfo
- Publication number
- WO2015174585A1 WO2015174585A1 PCT/KR2014/008242 KR2014008242W WO2015174585A1 WO 2015174585 A1 WO2015174585 A1 WO 2015174585A1 KR 2014008242 W KR2014008242 W KR 2014008242W WO 2015174585 A1 WO2015174585 A1 WO 2015174585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pancreatic cancer
- biomarker
- antibody
- protein
- complement factor
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/561—Immunoelectrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
Definitions
- the present application is a pancreatic cancer diagnostic kit comprising an antibody that specifically binds to a complement factor B protein and an antibody that specifically binds to a carbohydrate antigen 19-9 protein, a method for providing information for pancreatic cancer diagnosis using the same, and It relates to the pancreatic cancer diagnostic method used.
- Pancreatic cancer is the ninth most common cancer in the world, with the fourth highest mortality rate (Lowenfels, AB, et al., Best Pract Res Clin Gastroenterol, 197-209, 2006). In most countries, pancreatic cancer accounts for only 2-3% of all malignant tumors, but the death toll accounts for 6% of all tumor-related deaths. The reason for this is that the two-year survival rate of pancreatic cancer is only around 10%, and the prognosis is poor, with the 5-year survival rate not exceeding 5% (Lee, CN, et al., Pancreas , 94-94, 2012).
- pancreatic cancers don't show symptoms until they progress significantly, so once the pancreatic cancer is diagnosed, it is already very advanced, so surgery is often impossible. Even when surgery is possible, 80-90% of patients undergo recurrence and death. Radiotherapy and chemotherapy are performed in addition to surgery to treat pancreatic cancer, but most patients have limited effects on the survival of patients. Therefore, early diagnosis of pancreatic cancer is very important.
- Methods for diagnosing pancreatic cancer include biopsy using computed tomography (CT) or magnetic resonance imaging (MRI). Recently, a clinical sample for diagnosing pancreatic cancer is a body fluid such as plasma. Simultaneous measurement of protein in E. coli is used to determine the presence or possibility of pancreatic cancer.
- the most commonly used tumor marker associated with pancreatic cancer is carbohydrate antigen 19-9 (CA 19-9), but CA 19-9 is used in the plasma of cancer patients of the gastrointestinal system including biliary tract in addition to pancreatic cancer. It is known to be elevated, and also known to be elevated in cases of cholangitis and biliary obstruction without malignant tumors, there is a problem that the specificity is low. (Source: National Health Information Portal).
- CA 19-9 carbohydrate antigen 19-9
- CA 19-9 is used in the plasma of cancer patients of the gastrointestinal system including biliary tract in addition to pancreatic cancer. It is known to be elevated, and also known to be elevated in cases of cholangitis and
- CFB Complement factor b
- CFB Complement factor b
- Alternative pathways are activated by the sugar structure on the surface of pathogen cells, regardless of antigen-antibody complex formation. Activation is induced by first binding a small amount of C3b present in the blood to the microbial surface. When C3b binds to complement factor B in the blood, it is decomposed into C3bBb and Ba by complement factor D, and C3bBb is stabilized by properidine to become an alternative pathway to C3 convertase and produce more C3b. I enter the amplification phase.
- C3bBb3b complex exhibits the alternative pathway of C5 convertase activity, which breaks down C5 into C5a and C5b and finally forms MAC on the bacterial surface.
- C5 convertase activity breaks down C5 into C5a and C5b and finally forms MAC on the bacterial surface.
- bacteria die and antigens are removed.
- Complement B is known as a secreted protein that plays an important role in c5 production by binding to the c3b protein, an early stage of this alternative pathway, and has five glycan sites as glycoproteins.
- Complement B is known as ovarian cancer (Wu.J., et al., JPR , 4541-52, 2012), erythroidal cancer (Seriramalu. R., et al., Electrophoresis , 2388-95, 2010), breast cancer (Doustjalali, SR, et al., Electrophoresis , 2392-401, 2004) and are known to be secreted from the serum of various patients.
- complement factor B is known as ovarian cancer (Wu.J., et al., JPR , 4541-52, 2012)
- erythroidal cancer Stemasarcomasis , erythroidal cancer
- breast cancer Dantjalali, SR, et al., Electrophoresis , 2392-401, 2004
- pancreatic cancer no attempt has been made to diagnose pancreatic cancer by combining complement factor B with carbohydrate.
- the present application provides a pancreatic cancer diagnostic kit comprising an antibody specifically binding to the complement factor B protein, which is a novel biomarker for diagnosing pancreatic cancer, having an excellent specificity and sensitivity, and an antibody specifically binding to the carbohydrate antigen 19-9 protein,
- the present invention provides a method for providing information for diagnosing pancreatic cancer and a method for diagnosing pancreatic cancer using the same.
- the present application provides a method for diagnosing pancreatic cancer comprising measuring the protein expression level of complement factor B in a blood sample isolated from an individual, and a method for providing information for diagnosing pancreatic cancer.
- the present application also provides the use of complement factor B (CFB) as a diagnostic marker for pancreatic cancer.
- CFB complement factor B
- the present application provides a pancreatic cancer diagnostic kit comprising an antibody that specifically binds to the complement factor B protein.
- the complement factor B protein may be composed of the amino acid sequence of SEQ ID NO: 1.
- the subject may be a patient suspected of pancreatic cancer.
- the method may further comprise comparing the protein expression level of complement factor B in the blood sample isolated from the individual to the protein expression level of complement factor B in the normal control.
- a normal control means a blood sample isolated from a healthy individual without pancreatic cancer or other disease.
- the two pancreatic cancer samples may be compared and the candidate patient may be classified as a pancreatic cancer patient if the protein expression level of complement factor B of the sample of suspected pancreatic cancer is higher than the protein expression level of complement factor B of the normal control sample.
- the complement factor B protein level of the sample of the pancreatic cancer candidate patient is two times higher than the complement factor B protein level of the normal control sample, the candidate patient may be classified as a pancreatic cancer patient.
- the blood sample may be a whole blood, plasma or serum sample.
- diagnosis in the present application means identifying the presence or characteristic of a pathological condition. In light of the purpose of the present application, the diagnosis is to confirm the production and recurrence of pancreatic cancer.
- the term "diagnostic marker” or “diagnostic marker” is a substance that can diagnose cancer cells separately from normal cells, and increases or decreases polypeptides or nucleic acids (eg, mRNA) in cells with cancer compared to normal cells.
- Organic biomolecules such as lipids, glycolipids, glycoproteins or sugars (monosaccharides, disaccharides, oligosaccharides, etc.) and the like.
- pancreatic cancer diagnostic markers are genes of CA 19-9 and / or complement factor B and proteins encoded thereby that exhibit specific high levels of expression in pancreatic cancer cells as compared to cells of normal pancreatic tissue. .
- protein expression level measurement refers to a process of confirming the presence and expression level of a protein expressed in a cancer marker gene in a biological sample in order to diagnose cancer.
- An antibody that specifically binds to the protein of the gene. Check the amount of protein using. Western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket ) Immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS and protein chip, but are not limited thereto.
- Specifically binds in the present application means that the binding force to the target material is superior to other materials to the extent that the presence or absence of the target material can be detected by the binding.
- an “antibody” in this application refers to a peptide or polypeptide substantially derived from or made from an immunoglobulin gene or immunoglobulin genes, or fragments thereof, that can specifically bind an antigen or epitope.
- Antibodies in the present application include various forms of antibody structures, including but not limited to whole antibodies and antibody fragments.
- An antibody fragment comprises a portion of an antibody of full length, the variable domain of the antibody, or at least the antigen binding site of the antibody. Examples of antibody fragments include diabodies, single-chain antibody molecules and multispecific antibodies formed from antibody fragments.
- the antibody may be a polyclonal antibody or a monoclonal antibody.
- Antibodies against complement factor B proteins are commonly known in the art, such as fusion methods (Kohler and Milstein, European Journal of Immunology, 6: 511-519 (1976)), recombinant DNA methods (US patents). 4,816,56) or phage antibody library methods (Clackson et al, Nature, 352: 624-628 (1991) and Marks et al, J. Mol. Biol., 222: 58, 1-597 (1991)). Can be prepared by General procedures for antibody preparation are described in Harlow, E.
- sensitivity refers to the probability that the diagnostic test result will be positive when the disease is affected
- specificity means that the test result is negative when the disease is not affected. Indicates the degree of likelihood.
- Complement factor B protein was selected as a candidate for pancreatic cancer diagnostic markers, and the presence of complement factor B protein in the plasma of normal and pancreatic cancer patients was confirmed and the change was observed. As a result, it was confirmed that the protein expression level of complement factor B is very high in the plasma of pancreatic cancer patients compared to the normal control (Examples 1 and 2).
- ELISA and Receiver Operating Characteristic (ROC) curve analysis were performed to verify the efficacy of CFB as a pancreatic cancer diagnostic marker when compared to CA 19-9, which is known as a pancreatic cancer diagnostic marker, and their optimal cut-off values. The sensitivity and specificity of CFB and CA 19-9, respectively, were analyzed based on (Examples 3-6).
- CA 19-9 was increased in pancreatic cancer, liver cancer, bile duct cancer and gastric cancer, indicating that the specificity was decreased. That means that CA 19-9 alone is not suitable for use as a pancreatic cancer diagnostic marker.
- CFB expression was specifically increased only in pancreatic cancer, which means that it is suitable as a diagnostic marker for pancreatic cancer due to its excellent sensitivity and specificity.
- CA 19-9 alone has a problem of inferiority in specificity as a diagnostic marker for pancreatic cancer
- CA 19-9 was used together with CFB it was found that sensitivity and specificity were the best. This means that CA 19-9 alone is not suitable for use as a marker for diagnosing pancreatic cancer, but when used with CFB, pancreatic cancer can be diagnosed more accurately.
- the kit may further comprise an antibody that specifically binds carbohydrate antigen 19-9.
- the present application also provides methods for diagnosing pancreatic cancer and providing information for pancreatic cancer diagnosis comprising measuring protein expression levels of complement factor B and carbohydrate antigen 19-9 in blood samples isolated from the subject.
- the subject may be a suspected pancreatic cancer group.
- the blood sample may be a whole blood, plasma or serum sample.
- the present application also provides a method for diagnosing pancreatic cancer comprising measuring protein expression levels of complement factor B and carbohydrate antigen 19-9 as a biomarker for diagnosing pancreatic cancer,
- a second step of forming a complex of the antibody and the biomarker by contacting the blood sample with an antibody that specifically binds to the biomarker and is detectably labeled;
- the fifth step if the amount of the biomarker in the sample is greater than the amount of the control biomarker provides a pancreatic cancer diagnostic method comprising a sixth step of diagnosing pancreatic cancer.
- biomarker means complement factor B or carbohydrate 19-9.
- the amount of the biomarker can be known therefrom.
- the amount of control biomarker refers to the amount of biomarker in the blood sample of an individual without pancreatic cancer.
- the blood sample may be a whole blood, plasma or serum sample.
- the first step and the second step may further comprise the step of separating the biomarker and proteins other than the biomarker in the blood sample by immunoprecipitation.
- the step of separating the biomarker and protein other than the biomarker is
- the present invention also provides a method for treating pancreatic cancer comprising treating a subject with a pancreatic cancer therapeutic agent when diagnosed with pancreatic cancer according to the above method.
- Pancreatic cancer therapeutic agents can be used without limitation to known drugs known to be effective in treating pancreatic cancer.
- According to the present application can provide a diagnostic marker for pancreatic cancer with improved sensitivity and specificity.
- FIG. 1A shows two-dimensional electrophoresis images of normal plasma and FIG. 1B shows two-dimensional electrophoresis images of plasma of pancreatic cancer patients.
- the spot indicated by the arrow indicates complement factor B protein.
- Figure 2 shows the difference in the expression of complement factor B in the plasma of normal and pancreatic cancer patients shows a two-dimensional vertical electrophoresis image of the spot (black point) of Figures 1a and 1b.
- Figure 3a shows the results of Western blot analysis of the protein expression level of complement factor B in the plasma of normal and pancreatic cancer patients (N: normal, C: pancreatic cancer patients).
- 3B is a graph showing the intensity of the western blot band of FIG. 3A.
- Figure 4a shows the results of Western blot analysis of protein expression levels of complement factor B in normal cell lines (HPDE) and pancreatic cancer cell lines (HPAC1, BXPC3, PANC1).
- 4b shows the results of RT-PCR analysis of protein expression levels of complement factor B in normal cell lines (HPDE) and pancreatic cancer cell lines (HPAC1, BXPC3, PANC1).
- 4C is a graph showing the band strength of FIG. 1B.
- Figure 5a is the result of analyzing the protein expression level of complement factor B (CFB) by Western blot.
- HD is normal
- CP is pancreatitis
- PC is pancreatic cancer.
- 5B is a graph showing the intensity of the western blot band of FIG. 5A.
- HD is normal
- CP is pancreatitis
- PC is pancreatic cancer.
- CFB CFB
- CA 19-9 CFB
- HD normal
- CP pancreatitis
- PC pancreatic cancer
- HCC liver cancer
- CC cholangiocarcinoma
- GC gastric cancer.
- Figure 7 shows the ROC curves of CA 19-9, CFB and CFB + CA 19-9.
- Example 1-1 CFB Protein Detection in Plasma by Electrophoresis and Mass Spectrometry
- Electrophoresis and mass spectrometry were performed to detect the presence and amount of CFB in the plasma of normal and pancreatic cancer patients.
- Plasma was obtained from Severance Hospital Gene Bank and Gastroenterology Internal Medicine and was in accordance with the Institutional Review Board (IRB) regulations. Plasma samples were dispensed 200 ⁇ l each and stored at -70 ° C until the experiment.
- Complement factor B is a secreted protein, and since plasma contains a large amount of known high abundance proteins, Hu-14 (Agilent) is used to remove proteins other than complement factor B.
- Two-dimensional fluorescence electrophoresis was performed. For two-dimensional electrophoresis, for each sample of 10 normal plasma and 10 pancreatic cancer patients, 50 ⁇ g of each sample and the corresponding standard sample were treated with dark dye 400 pmol Cy3, Cy5, Cy2 (GE Healthcare).
- Tributylphosphine buffer [6 M urea, 2% sodium dodecyl sulfate (SDS), 30 mM tris, 20% glycerol, 2.5% acrylamide solution, 5 mM Tributylphosphine] for one-minute reduction and alkylation.
- FIG. 1A The results of two-dimensional electrophoresis on the plasma of normal persons are shown in FIG. 1A, and the results of two-dimensional electrophoresis on the plasma of pancreatic cancer patients are shown in FIG. 1B.
- Arrows in the figures represent CFBs. As a result, it was found that the expression of CFB was increased in pancreatic cancer patients.
- Secondary vertical electrophoresis was performed to investigate the difference in the expression of CFB in the plasma of normal and pancreatic cancer patients. Secondary electrophoresis was performed using 9% ⁇ 16% polyacrylamide gel using Ettan Dalttwelve electrophoresis system (GE Healthcare), and after the electrophoresis, Cy2, using Typhoon 9400 (GE Healthcare) scanner Scanning at a wavelength corresponding to Cy3, Cy5. Each gel image was analyzed using DeCyder 2-D analysis software (GE Healthcare).
- Anti-Complement Factor B antibody (CFB, Abcam) was firstly diluted 1: 1000-fold in TBS-T buffer solution containing 5% skim milk and anti-mouse IgG-HRP (Santa Cruz) 1: 10000 times was treated secondly. The final NC membrane was reacted for 1 minute with ECL Plus Western Blot Reagent (GE Healthcare) and analyzed by scanning with a Typhoon 9400 scanner.
- CFB Anti-Complement Factor B antibody
- RT-PCR was used to confirm mRNA expression levels of CFB.
- Total RNA was extracted using easy-BLUE (iNtRON, Gyeonggi, Korea), and cDNA was synthesized using an omniscript RT kit (Qiagen, Hilden, Germany).
- the primers used are as follows:
- CFB primer (SEQ ID NO: 2): 5'-CAACAGAAGCGGAAGATCGTC-3 '(forward)
- GAPDH Primer (SEQ ID NO: 4): 5'-ACCACAGTCCATGCCATCAC-3 '(forward)
- GAPDH Primer (SEQ ID NO: 5): 5'-TCCACCACCCTGTTGCTGTA-3 '(Reverse)
- Western blots were performed in the same manner as in Example 1-3 using pooled samples. As a result, it was confirmed that CFB was expressed higher in PC than HD and CP (FIG. 5A). As a result, the intensity of these western blot bands was represented by a point p ⁇ 0.05. It was shown to be highly expressed (FIG. 5B). Therefore, even when using a large patient population and independent experiments, it was confirmed that CFB was significantly expressed on the PC twice as high as HD and CP.
- ELISA tests were performed using plasma of HD, CP, PC, HCC, CC, and GC to compare the expression levels of CA 19-9 and CFB, now known as pancreatic cancer biomarkers.
- CFB and CA 19-9 ELISA KIT used USCN and Panomics products respectively, and each product was tested according to each protocol.
- each plasma was diluted 1: 10,000 and then 100 ul each was put in a well coated with antibodies against CFB. Incubate at room temperature for 2 hours. Thereafter, plasma was removed from the well, and 100ul of detection reagent A working solution was added thereto, followed by incubation at room temperature for 1 hour. After 1 hour, the solution was removed from the well, and 350 ul of washing solution was added and washed three times. Thereafter, 100 ul of the detection reagent B working solution was added to each well and reacted at room temperature for 30 minutes. The wash solution was washed five times. Subsequently, 90ul of substrate solution was added to each well, and then reacted under dark conditions for 15 minutes.
- CA 19-9 ELISA 10ul of each plasma was put on a plate coated with CA 19-9 antibody and 100ul CA 19-9 assay buffer was put thereon. After mixing well for 30 seconds and incubated for 90 minutes at room temperature. The buffer was then removed from the wells and washed four times using wash buffer. Thereafter, 100 ul of working conjugate reagent was added to each well, mixed well for 30 seconds, and then incubated at room temperature for 90 minutes. Reagents were removed from the wells and washed four times using wash buffer. Thereafter, TMB was added to each well, mixed for 10 seconds, and reacted for 20 minutes under dark conditions.
- CA 19-9 alone is not suitable for use as a pancreatic cancer diagnostic marker
- CFB whose expression is specifically increased in pancreatic cancer, is suitable as a diagnostic marker for pancreatic cancer.
- ROC curve analysis was performed using the Mann-Whitney rank sum test program to determine how CFB and CA 19-9 distinguish between pancreatic cancer patients and non-humans (HD, CP, HCC, CC, GC).
- AUC values were used to compare CFB and CA 19-9.
- the CFB showed 0.958 (95% CI: 0.956-0.959), which showed higher AUC than 0.833 (95% CI: 0.829-0.837) of CA 19-9.
- the AUC of the two combinations (CFB + CA 19-9) was 0.986 (0.985-0.986), which was significantly higher than that of CFB and CA 19-9 ( p ⁇ 0.01) alone (Fig. 7).
- pancreatic cancer can be diagnosed by CFB alone or by a combination of CFB and CA 19-9.
- CA 19-9 For each group (HD; normal, CP; pancreatitis, PC; pancreatic cancer, HCC; liver cancer, CC; bile duct cancer, GC; gastric cancer), the diagnostic efficiency of CA 19-9 and CFB was confirmed. As a result, as shown in Table 2, both CA 19-9 and CFB showed similar diagnostic efficiency in the PC (CA 19-9: 80.5%, CFB: 73.2%). However, CA 19-9 showed high diagnostic efficiency (HCC: 61.3%, CC: 77.2%, GC: 17.1%) in other cancers (HCC, CC, GC), while CFB showed low diagnostic efficiency in other cancers. HCC: 0%, CC: 0%, GC: 8.6%). This means that CFB is more specific to PC than CA 19-9 when compared to other cancers.
- CA 19-9 and CFB + CA 19-9 as pancreatic cancer diagnostic indicators, CA 19-9, CFB and according to the optimal cut-off value predicted by the maximum Youden index
- the sensitivity and specificity (%) of pancreatic cancer diagnosis compared to other diseases of CFB + CA 19-9 were confirmed.
- Table 3 when comparing the PC and other groups (HD, CP, HCC, CC, GC), the sensitivity of CA 19-9 was 80.4%, specificity was 70.0% and CFB was The sensitivity was 73.1% and specificity 97.9%. When combined with CFB and CA 19-9, the sensitivity was 90.1% and specificity 97.2%. This means that when CA 19-9 and CFB are used alone, better diagnostic efficiency is obtained when CA 19-9 and CFB are used alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Electrochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (13)
- 개체로부터 분리된 혈액 시료 내의 보체인자 B 및 카보하이드레이트 안티젠 19-9의 단백질 발현 수준을 측정하는 것을 포함하는 췌장암 진단을 위한 정보의 제공 방법.
- 제1항에 있어서, 개체로부터 분리된 혈액 시료 내의 보체인자 B 및 카보하이드레이트 안티젠 19-9의 단백질 발현 수준을 정상 대조군 내의 보체인자 B 및 카보하이드레이트 안티젠 19-9의 단백질 발현 수준과 각각 비교하는 단계를 추가로 포함하는 췌장암 진단을 위한 정보의 제공 방법.
- 제1항에 있어서, 혈액 시료는 전혈, 혈장 또는 혈청 시료인 췌장암 진단을 위한 정보의 제공 방법.
- 제1항에 있어서, 보체인자 B 및 카보하이드레이트 안티젠 19-9의 단백질 발현 수준은 2차원 형광전기영동, 웨스턴블롯팅, ELISA, 방사선 면역분석, 방사면역확산법, 면역전기영동 또는 질량분석을 이용하여 측정하는 것인 췌장암 진단을 위한 정보의 제공 방법.
- 보체인자 B에 특이적으로 결합하는 항체 및 카보하이드레이트 안티젠 19-9에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트.
- 제5항에 있어서, 보체인자 B는 서열번호 1의 아미노산 서열로 이루어진 췌장암 진단용 키트.
- 제5항에 있어서, 항체는 폴리클로날 항체 또는 모노클로날 항체인 췌장암 진단용 키트.
- 췌장암 진단용 바이오마커로서 보체인자 B 및 카보하이드레이트 안티젠 19-9의 단백질 발현 수준을 측정하는 것을 포함하는 췌장암 진단 방법에 있어서,개체로부터 혈액 시료를 수집하는 제1단계;바이오마커에 특이적으로 결합하고 검출 가능하게 표지된 항체에 상기 혈액 시료를 접촉하여 상기 항체 및 상기 바이오마커의 복합체를 형성하는 제2단계;복합체를 포함하지 않는 표지된 항체로부터 상기 제2단계에서 형성된 복합체를 분리하는 제3단계;상기 제2단계에서 형성된 복합체를 포함하는 항체의 검출 가능한 표지로부터 신호를 정량하여 상기 혈액 시료 내의 바이오마커의 양을 측정하는 제4단계;상기 제4단계에서 측정된 바이오마커의 양과 대조군 바이오마커의 양을 비교하는 제5단계; 및상기 제5단계에서 시료에서 바이오마커의 양이 대조군 바이오마커의 양보다 많은 경우 췌장암으로 진단하는 제6단계를 포함하는 췌장암 진단 방법.
- 제8항에 있어서,대조군 바이오마커의 양은 췌장암이 없는 개체의 혈액 시료 내의 바이오마커의 양인 췌장암 진단 방법.
- 제8항에 있어서,혈액 시료는 전혈, 혈장 또는 혈청 시료인 췌장암 진단 방법.
- 제8항에 있어서,제1단계와 제2단계 사이에,면역 침강에 의하여 혈액 시료 내의 바이오마커 외의 단백질과 바이오마커를 분리하는 단계를 추가로 포함하는 췌장암 진단 방법.
- 제11항에 있어서, 바이오마커 외의 단백질과 바이오마커를 분리하는 단계는i) 개체로부터 분리된 혈액 시료를 바이오마커에 특이적으로 결합하는 항체와 접촉하여 상기 항체와 상기 바이오마커 사이에 복합체를 형성하는 단계;ii) 상기 i) 단계에서 형성된 복합체를 침강시키는 단계;iii) 바이오마커 외의 다른 단백질 및 복합체를 형성하지 않은 항체를 포함하는 시료의 상청액으로부터 침강된 복합체를 분리하는 단계를 포함하는 췌장암 진단 방법.
- 제8항의 방법에 따라 췌장암으로 진단되는 경우, 개체에게 췌장암 치료제를 처리하는 것을 포함하는 췌장암 치료 방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL14892029T PL3144676T3 (pl) | 2014-05-12 | 2014-09-03 | Zestaw zawierający przeciwciało swoiście wiążące białko stanowiące czynnik b dopełniacza oraz przeciwciało swoiście wiążące białko stanowiące antygen węglowodanowy 19-9 do diagnozowania raka trzustki |
EP14892029.1A EP3144676B1 (en) | 2014-05-12 | 2014-09-03 | Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer |
ES14892029T ES2776733T3 (es) | 2014-05-12 | 2014-09-03 | Kit que comprende un anticuerpo que se une específicamente a la proteína del factor B del complemento y un anticuerpo que se une específicamente a la proteína del antígeno carbohidrato 19-9 para el diagnóstico del cáncer pancreático |
JP2016567615A JP6361943B2 (ja) | 2014-05-12 | 2014-09-03 | 補体因子bタンパク質に特異的に結合する抗体及び糖鎖抗原19−9タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット |
CN201480078913.3A CN106461665B (zh) | 2014-05-12 | 2014-09-03 | 用于诊断胰腺癌的包括补体因子b蛋白的抗体和糖类抗原19-9蛋白的抗体的试剂盒 |
DK14892029.1T DK3144676T3 (da) | 2014-05-12 | 2014-09-03 | Kit omfattende antistof der specifikt binder til komplementfaktor b protein og antistof der specifikt binder til kulhydratantigen 19-9 protein til diagnosticering af cancer i bugspytkirtlen |
US15/347,812 US10656154B2 (en) | 2014-05-12 | 2016-11-10 | Methods for detecting an amount of complement factor B protein and carbohydrate antigen 19-9 protein, and methods for diagnosing and treating pancreatic cancer using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0056585 | 2014-05-12 | ||
KR1020140056585A KR20150129932A (ko) | 2014-05-12 | 2014-05-12 | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/347,812 Continuation-In-Part US10656154B2 (en) | 2014-05-12 | 2016-11-10 | Methods for detecting an amount of complement factor B protein and carbohydrate antigen 19-9 protein, and methods for diagnosing and treating pancreatic cancer using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015174585A1 true WO2015174585A1 (ko) | 2015-11-19 |
Family
ID=54480106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/008242 WO2015174585A1 (ko) | 2014-05-12 | 2014-09-03 | 보체인자 b 단백질에 특이적으로 결합하는 항체 및 카보하이드레이트 안티젠 19-9 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10656154B2 (ko) |
EP (1) | EP3144676B1 (ko) |
JP (1) | JP6361943B2 (ko) |
KR (1) | KR20150129932A (ko) |
CN (1) | CN106461665B (ko) |
DK (1) | DK3144676T3 (ko) |
ES (1) | ES2776733T3 (ko) |
PL (1) | PL3144676T3 (ko) |
PT (1) | PT3144676T (ko) |
WO (1) | WO2015174585A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11320436B2 (en) | 2020-07-16 | 2022-05-03 | Immunovia Ab | Methods, arrays and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2140269T3 (pl) | 2007-03-27 | 2014-07-31 | Immunovia Ab | Podpis białkowy/znaczniki do wykrywania gruczolakoraka |
GB201608192D0 (en) * | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
KR102289278B1 (ko) * | 2019-07-09 | 2021-08-13 | 주식회사 베르티스 | 췌장암 진단용 바이오마커 패널 및 그 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012120288A2 (en) * | 2011-03-04 | 2012-09-13 | Immunovia Ab | Method, array and use thereof |
KR20130034505A (ko) * | 2011-09-28 | 2013-04-05 | 사회복지법인 삼성생명공익재단 | 카텝신 d와 매트릭스 메탈로프로틴나제-7의 측정수단을 포함하는 췌장암 진단용 키트 |
KR20130116433A (ko) * | 2012-03-19 | 2013-10-24 | 서울대학교산학협력단 | 췌장암 진단용 마커 및 이의 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63159763A (ja) * | 1986-12-24 | 1988-07-02 | Fujirebio Inc | 逆受身凝集反応試薬 |
CN1726395A (zh) * | 2002-12-17 | 2006-01-25 | 北京诺赛基因组研究中心有限公司 | 胰腺癌的特异标记 |
AU2003294828A1 (en) | 2002-12-17 | 2004-07-09 | Sinogenomax Co. Ltd. Chinese National Human Genomecenter | Specific markers for pancreatic cancer |
JP2007051880A (ja) * | 2005-08-15 | 2007-03-01 | Tokyo Univ Of Science | 膵臓癌の検出方法、膵臓癌の診断キット |
RU2008139098A (ru) * | 2006-03-02 | 2010-04-10 | Онкотерапи Сайенс, Инк. (Jp) | Способы диагностики рака поджелудочной железы с применением белка reg4 |
PL2140269T3 (pl) * | 2007-03-27 | 2014-07-31 | Immunovia Ab | Podpis białkowy/znaczniki do wykrywania gruczolakoraka |
CN102137681B (zh) * | 2008-08-08 | 2014-12-03 | 埃姆诺医药有限公司 | 抗胰腺癌抗体 |
AU2011289284B2 (en) * | 2010-08-13 | 2015-04-09 | Somalogic Operating Co., Inc. | Pancreatic cancer biomarkers and uses thereof |
TWI408370B (zh) * | 2011-05-19 | 2013-09-11 | Univ Chang Gung | 胰臟癌之血清生物檢測標誌及其應用 |
JP2014020930A (ja) * | 2012-07-18 | 2014-02-03 | Kanazawa Univ | 膵癌診断及び治療効果予測判定バイオマーカー |
-
2014
- 2014-05-12 KR KR1020140056585A patent/KR20150129932A/ko active Application Filing
- 2014-09-03 CN CN201480078913.3A patent/CN106461665B/zh active Active
- 2014-09-03 WO PCT/KR2014/008242 patent/WO2015174585A1/ko active Application Filing
- 2014-09-03 JP JP2016567615A patent/JP6361943B2/ja active Active
- 2014-09-03 PL PL14892029T patent/PL3144676T3/pl unknown
- 2014-09-03 ES ES14892029T patent/ES2776733T3/es active Active
- 2014-09-03 EP EP14892029.1A patent/EP3144676B1/en active Active
- 2014-09-03 PT PT148920291T patent/PT3144676T/pt unknown
- 2014-09-03 DK DK14892029.1T patent/DK3144676T3/da active
-
2016
- 2016-11-10 US US15/347,812 patent/US10656154B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012120288A2 (en) * | 2011-03-04 | 2012-09-13 | Immunovia Ab | Method, array and use thereof |
KR20130034505A (ko) * | 2011-09-28 | 2013-04-05 | 사회복지법인 삼성생명공익재단 | 카텝신 d와 매트릭스 메탈로프로틴나제-7의 측정수단을 포함하는 췌장암 진단용 키트 |
KR20130116433A (ko) * | 2012-03-19 | 2013-10-24 | 서울대학교산학협력단 | 췌장암 진단용 마커 및 이의 용도 |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI 5 June 2000 Derwent World Patents Index; * |
LEE, MIN JUNG ET AL.: "Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma", JOURNAL OF PROTEOME RESEARCH, vol. 13, no. 11, 24 July 2014 (2014-07-24), pages 4878 - 4888, XP055236746 * |
PANG, WEI WEI ET AL.: "Can the acute-phase reactant proteins be used as cancer biomarkers?", THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 25, no. 1, 2010, pages 1 - 11, XP055236728 * |
See also references of EP3144676A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11320436B2 (en) | 2020-07-16 | 2022-05-03 | Immunovia Ab | Methods, arrays and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3144676A1 (en) | 2017-03-22 |
KR20150129932A (ko) | 2015-11-23 |
PL3144676T3 (pl) | 2020-07-13 |
PT3144676T (pt) | 2020-03-23 |
CN106461665A (zh) | 2017-02-22 |
EP3144676B1 (en) | 2019-12-11 |
US20170153239A1 (en) | 2017-06-01 |
CN106461665A8 (zh) | 2017-06-30 |
JP6361943B2 (ja) | 2018-07-25 |
ES2776733T3 (es) | 2020-07-31 |
JP2017526896A (ja) | 2017-09-14 |
US10656154B2 (en) | 2020-05-19 |
CN106461665B (zh) | 2019-01-25 |
EP3144676A4 (en) | 2017-09-27 |
DK3144676T3 (da) | 2020-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020202066B2 (en) | Methods and compositions for detecting pancreatic cancer | |
WO2015182580A1 (ja) | 大腸がんの転移検出方法 | |
WO2022063156A1 (zh) | 乳腺癌的生物标志物及其应用 | |
WO2017222221A1 (ko) | 포타슘 채널 단백질을 이용한 암 진단용 조성물 | |
WO2015174585A1 (ko) | 보체인자 b 단백질에 특이적으로 결합하는 항체 및 카보하이드레이트 안티젠 19-9 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 | |
CN109313192B (zh) | 核小体-转录因子复合体用于癌症检测的用途 | |
ES2402564T3 (es) | Uso de EEF1A como biomarcador para el cribado de inhibidores de METAP2 | |
JP4515099B2 (ja) | Lasp−1免疫反応性の決定によって炎症性疾患および感染を診断するための方法 | |
KR20090029868A (ko) | 체액 내 간암 마커로서의 아넥신 2 및 이를 이용한 간암진단 키트 | |
WO2021045180A1 (ja) | 胃がんマーカー、及びこれを用いた検査方法 | |
JPWO2011138955A1 (ja) | Siaα2−8Siaα2−3Galβ−R糖鎖を持つムチン1の分析方法 | |
WO2021172926A1 (ko) | 암의 진단용 조성물 | |
KR102128251B1 (ko) | 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
KR101594287B1 (ko) | 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트 | |
WO2019022370A1 (ko) | 위암 진단용 조성물 및 상기 조성물을 이용한 위암 진단 방법 | |
KR102316892B1 (ko) | 암의 진단용 조성물 | |
KR102433983B1 (ko) | 암의 진단용 조성물 | |
KR20110129508A (ko) | 폐암 바이오마커 | |
WO2024117803A1 (ko) | 췌장암의 예후 예측을 위한 새로운 바이오 마커 | |
WO2021118243A1 (ko) | Wasf2 자가항체를 이용한 간세포암종 조기진단용 조성물 | |
CN106459166B (zh) | 检测肉瘤转移的方法和生物标记物 | |
KR20130023308A (ko) | 폐암 바이오마커 | |
KR101652894B1 (ko) | 대장암에 대한 신규 바이오마커 및 그의 용도 | |
KR20140094180A (ko) | 보체인자 b 단백질에 특이적으로 결합하는 폴리펩타이드 또는 항체를 포함하는 췌장암 진단용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14892029 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016567615 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014892029 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014892029 Country of ref document: EP |